Journal Information
Vol. 31. Issue 4.
Pages 157-161 (April 1995)
Share
Share
Download PDF
More article options
Vol. 31. Issue 4.
Pages 157-161 (April 1995)
Full text access
Engrosamiento pleural en el derrame pleural tuberculoso. Factores asociados
Pleural thickening in tuberculosis pleural effusion. Associated factors
Visits
3621
J.J. Soler*, V. Gil Suay, P. Cordero, M. Perpiñá, E. Martínez, J. Sanchis
Servicio de Neumología. Hospital Universitario La Fe. Valencia
This item has received
Article information
Abstract
Bibliography
Download PDF
Statistics

Nuestro objetivo ha sido determinar qué factores se relacionan con el desarrollo de engrosamiento pleural residual (EPR) al finalizar el tratamiento específico.

Se estudian 62 pacientes diagnosticados de tuberculosis pleural (TP), separados en 2 grupos en función de la presencia o ausencia de EPR > 2 mm en la porción lateral e inferior de una radiografía posteroanterior de tórax, al finalizar el tratamiento específico. Ningún paciente recibió corticoides. El 72,6% presentó engrosamiento, siendo este más frecuente entre los varones (odds ratio, 4,06; p = 0,034), y en los enfermos de edad media superior, 36 ± 21 frente a 27 ± 12 años (p = 0,05). El hábito tabáquico, tamaño del derrame, duración de la sintomatología, encapsulamiento, PPD, biopsia pleural, bacteriología y el pH, glucosa, proteínas y colesterol del líquido pleural, así como sus respectivos cocientes pleura/suero fueron similares en ambos grupos. La LDH pleural (LDHp) y su relación pleura/suero (LDHp/s) fue 454,3 ± 234,6 U/l y 3,21 ± 1,67 en el grupo con EPR, por 306,0 ± 137,2 U/l y 2,00 ± 1,16 del grupo sin secuelas (p = 0,004 y p = 0,016, respectivamente). Utilizando como punto de corte una LDH p/s superior a 2,10, la sensibilidad obtenida fue del 78,9% con especificidad del 71,4%, valor predictivo positivo del 88,2% y valor predictivo negativo del 55,5%.

Concluimos que: a) el EPR es una complicación frecuente; b) de predominio masculino; c) que guarda relación con la edad, y d) un valor superior a 2,10 en la relación LDH p/s puede predecir con aceptable seguridad la presencia de este trastorno.

Palabras clave:
Tuberculosis pleural
Engrosamiento pleural

We aimed to determine which factors were related to the development of residual pleural thickening (RPT) after completion of prescribed treatment.

Sixty-two patients with pleural tuberculosis (PTB) were assigned to 2 groups according to the presence or absence of RPT > 2 mm in the side and lower portion of a chest film after completion of prescribed treatment. No patient had been given corticoids. Thickening developed in 72.6%, more often in men (OR, 4.06; p = 0.034), in older patients (36 ± 21 versus 27 ± 12 years; p = 0.05). Smoking, size of effusion, duration of symptoms, encapsulation, PPD, pleural biopsy, bacteriology and pH, glucose, proteins and cholesterol in pleural fluids, as well as their respective pleura/serum coefficients, were similar in both groups. Pleural LDH (LDHp) and its pleura/serum coefficient (LDHp/LDHs) were 454.3 ± 234.6 U/l and 3.21 ± 1.67 U/l in the group with RPT and 306.0 ± 137.2 U/l and 2.00 ± 1.16 in the group with no sequelae (p = 0.004 and p = 0.016, respectively). Using 2.10 as the cutoff for LDHp/LDHs, sensitivity was 78.9% and specificity was 71.4%, giving a positive predictive value of 88.2% and a negative predictive value of 55.5%.

We conclude that RPT a) is a frequent complication, b) is mainly found in men, c) is age-related and d) can be fairly safely predicted using 2.10 as the cutoff for LDHp/LDHs.

Key words:
Pleural tuberculosis
Pleural thickening
Full text is only aviable in PDF
Bibliografía
[1.]
R. Vidal, J. De Gracia, J. Ruiz, E. Fite, E. Monsó, N. Martín.
Estudio controlado de 637 pacientes con tuberculosis: diagnóstico y resultados terapéuticos con esquemas de 9 y 6 meses.
Med Clin (Barc), 87 (1986), pp. 368-370
[2.]
J.G. Weg.
Clinical forms of mycobacterial diseases.
Pulmonary diseases and disorders, 2. a, pp. 1.843-1.862
[3.]
A.K. Dutt, D. Moers, W.W. Stead.
Tuberculous pleural effusion: 6-month therapy with isoniazid and rifampin.
Am Rev Respir Dis, 145 (1992), pp. 1.429-1.432
[4.]
C.H. Lee, W.J. Wang, R.S. Lan, Y.F.I. Tsai, Y.C. Chiang.
Corticosteroids in the treatment of tuberculous pleurisy. A double-blind, placebo-controlled, randomized study.
Chest, 94 (1988), pp. 1.256-1.259
[5.]
G. Neummann.
Zur epidemiologie der pleuritis tuberculosa in der Bundesrepublik Deutschland.
Prax KJin Pneumol, 38 (1984), pp. 392-396
[6.]
C.H.S. Chan, M. Arnold, C.Y. Chan, T.W.L. Mak, G.B. Hoheisel.
Clinical and pathological features of tuberculous pleural effusion and its long-term consequences.
Respiration, 58 (1991), pp. 171-175
[7.]
C.S. Barbas, A. Cukier, C.R. Varvalho, J.V. Barbas, R.W. Light.
The relationship between pleural fluid fíndings and the Development of pleural thickening in patient with pleural tuberculosis.
Chest, 100 (1991), pp. 1.264-1.267
[8.]
P. Tani, H. Poppius, J. Makipaja.
Cortisone therapy for exudative tuberculous pleurisy in the light of follow-up study.
Acta Tuberc Scand, 44 (1964), pp. 303-309
[9.]
K.S. Mathur, J.S. Mathur, R.P. Sapru.
Treatment of tuberculous pleural effusion with local instillation of hydrocortisone.
Dis Chest, 47 (1965), pp. 83-87
[10.]
M.H.D. Smith, N. Matsaniotis.
Treatment of tuberculous pleural effusions with particular reference to adrenal corticosteroids.
Pediatrics, 22 (1958), pp. 1.074-1.087
[11.]
S.S. Paley, J.P. Mihaly, E.L. Mais, S.A. Gittens, B. Lupini.
Prednisone in the treatment of tuberculous pleural effusions.
Am Rev Tuberc, 79 (1959), pp. 307-314
[12.]
S.E. Large, R.K. Levick.
Aspiration in the treatment of primary tuberculous pleural effusion.
BMJ, 1 (1958), pp. 1.512-1.514
[13.]
R.G. Lahita.
Sex steroids and the rheumatic diseases.
Arthritis Rheum, 28 (1985), pp. 121-162
[14.]
H. Carlsten, R. Holmdahl, A. Tarkowski, Nilsson.
Oestradiol-and testoreone-mediated effects on the immune system in normal and autoinmune mice are genetically linked and inherited as dominant traits.
Immunology, 68 (1989), pp. 209-214
[15.]
E. Josefsson, A. Tarkowski, H. Carlsten.
Anti-inflammatory properties of estrogen.
Cell-Immunol, 142 (1992), pp. 67-78
[16.]
R.W. Light.
Pleural diseases.
2.a ed., Lea and Febiger, (1990),
[17.]
R.W. Light.
Lactate dehydrogenase isoenzymes in pleural effusions.
Am Rev Respir Dis, 108 (1973), pp. 660-664
[18.]
C. Albera, I. Mabritto, P. Ghio, G.V. Scagliotti, E. Pozzi.
Lymphocyte subpopulations analysis in pleural fluid and peripheral blood in patients with lymphocytic pleural effusions.
Respiration, 58 (1991), pp. 65-71
[19.]
T. Petterson, M. Klockars, P.E. Hellstrom, H. Riska, A. Wangel.
T and B lymphocytes in pleural effusions.
Chest, 73 (1978), pp. 4951
[20.]
E. Ribera, I. Ocaña, J.M. Martínez-Vázquez, M. Rosell, T. Español, A. Ruibal.
High level of interferon gamma in tuberculous pleural effusion.
Chest, 93 (1988), pp. 308-311
[21.]
J. Kelly.
Cytokines of the lung.
Am Rev Respir Dis, 141 (1990), pp. 765-788
[22.]
K. Shimokata, H. Saka, T. Murate, Y. Hasegawa, T. Hasegawa.
Cytokine content in pleural effusion. Comparison between tuberculous and carcinomatous pleurisy.
Chest, 99 (1991), pp. 1.103-1.107
Copyright © 1995. Sociedad Española de Neumología y Cirugía Torácica
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?